Treatment of Hypertension in Tibetan Adult Population

• Status: Unknown status
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Several surveys had revealed that Tibetan adults had high prevalence of hypertension. However, there was no research studying the antihypertensive effect of the known drugs in Tibetan. The main arms of our study were to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between nitrendipine and Hydrochlorothiazide in mild hypertension in Tibetan, and to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between captopril plus Hydrochlorothiazide and Beijing hypotensive No.0 in moderate and severe Tibetan hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West China Hospital
• Treatments: Antihypertensive Agents; Captopril; Hydrochlorothiazide; Nitrendipine

Criteria

Inclusion Criteria:

1. Adult Tibetan, who have been living in the Tibetan Plateau since he/she was born.

2. Consistent with diagnosed hypertension, blood pressure, for 1-3 grade.

3. Aged 18-80 years old.

4. To sign informed consent.

Exclusion Criteria:

1. diagnosis of secondary hypertension

2. Hypertensive emergencies and urgencies

3. Malignant hypertension

4. Bilateral renal artery stenosis, Chronic Kidney Disease（CKD）, serum creatinine> 133μmol / L.

5. Suffering from congenital heart disease, rheumatic heart disease, hypertrophic cardiomyopathy, aortic stenosis.

6. Occurred within the past 6 months who had a stroke or transient ischemic attack (TIA), unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA).

7. clinical significance of arrhythmia

8. Active liver disease, history of chronic persistent hepatitis, alanine aminotransferase（ALT）> upper limit of normal.

9. Pregnancy, pregnancy or breast-feeding women to prepare.